MORRISTOWN, N.J., Dec. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 8mg ramelteon tablets prior to the expiration of a patent owned by Takeda Pharmaceutical Company Limited. Watson’s 8mg ramelteon tablet product is a generic version of Takeda’s Rozerem(R), which is indicated for the treatment of insomnia characterized by difficulty with sleep onset.
For the twelve months ending September 30, 2009, Rozerem(R) had total U.S. sales of approximately $91 million according to IMS Health data.
For press release and other company information, visit Watson Pharmaceuticals’ Web site at http://www.watson.com.
Rozerem(R) is a registered trademark of Takeda Pharmaceutical Company Limited.
CONTACT: investors, Patty Eisenhaur, +1-973-355-8141, or media, Charlie
Mayr, +1-973-355-8483, both of Watson Pharmaceuticals, Inc.
Web site: http://www.watson.com/
